Aarey Drugs & Pharmaceuticals Limited
NSE: AAREYDRUGS
NSE
70.77
-1.53 (-2.12%)
Prev Close
72.3
Open Price
71.99
Volume
73,608
Today Low / High
70.19 / 72.39
52 WK Low / High
32.85 / 100
Range
67 - 74
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 70.77, with a change of -1.53 (-2.11618%). The expected target range on the NSE is between 67 - 74. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
26 Dec
71.99
-1.69%
24 Dec
71.05
1.76%
23 Dec
71.84
0.61%
22 Dec
71.43
0.57%
19 Dec
66.97
2.30%
18 Dec
67.41
-1.59%
17 Dec
67.00
1.57%
16 Dec
64.01
5.70%
15 Dec
66.27
-1.40%
12 Dec
65.25
2.94%
11 Dec
63.01
6.44%
10 Dec
68.24
-4.34%
09 Dec
68.24
0.00%
08 Dec
75.00
-4.23%
05 Dec
76.89
-1.65%
04 Dec
73.49
7.27%
03 Dec
77.61
-0.32%
02 Dec
85.73
-5.00%
01 Dec
87.40
-1.91%
28 Nov
88.49
-0.90%
Aarey Drugs & Pharmaceuticals Limited Graph
Aarey Drugs & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarey Drugs & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 70.77, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 70.77 | 71.48 | 64.33 - 78.63 |
| 72.19 | 57.75 - 86.62 | ||
| 72.89 | 51.03 - 94.76 | ||
| Bearish Scenario | 70.77 | 70.06 | 63.06 - 77.07 |
| 69.35 | 55.48 - 83.23 | ||
| 68.65 | 48.05 - 89.24 |
Overview of Aarey Drugs & Pharmaceuticals Limited
ISIN
INE198H01019
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
114,207
Market Cap
2,006,634,023
Last Dividend
0
Official Website
IPO Date
2021-08-06
DCF Diff
111.59
DCF
-41
Financial Ratios Every Investor Needs
Stock Dividend of AAREYDRUGS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2018-12-13 | December 13, 18 | 0.1 | 0.1 | 2018-12-14 | 2018-12-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 473.94 Cr | 464.81 Cr | 9.13 Cr | 0.0193 | 0.00 Cr | 1.34 Cr | 0.31 Cr | 4.02 Cr | 1.43 | 12.06 Cr | 0.0085 |
| 2024-03-31 | 395.10 Cr | 381.90 Cr | 13.20 Cr | 0.0334 | 0.00 Cr | 0.42 Cr | 2.82 Cr | 4.68 Cr | 1.84 | 11.42 Cr | 0.0119 |
| 2023-03-31 | 418.96 Cr | 403.84 Cr | 11.51 Cr | 0.0275 | 0.00 Cr | 0.88 Cr | 13.53 Cr | 3.77 Cr | 1.49 | 10.45 Cr | 0.0090 |
| 2022-03-31 | 491.61 Cr | 472.06 Cr | 19.54 Cr | 0.0398 | 0.00 Cr | 0.61 Cr | 11.77 Cr | 6.55 Cr | 2.72 | 14.06 Cr | 0.0133 |
| 2021-03-31 | 347.89 Cr | 337.79 Cr | 10.10 Cr | 0.0290 | 0.00 Cr | 0.32 Cr | 3.87 Cr | 6.51 Cr | 2.79 | 11.67 Cr | 0.0187 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.47 Cr | 238.27 Cr | 99.79 Cr | 138.4805 Cr | 34.86 Cr | 33.38 Cr | 45.48 Cr | 16.22 Cr | 0.00 Cr | 0.00 Cr | 3.10 Cr | 96.8804 Cr |
| 2024-03-31 | 1.59 Cr | 303.29 Cr | 170.52 Cr | 132.7734 Cr | 31.35 Cr | 29.76 Cr | 71.99 Cr | 12.96 Cr | 0.00 Cr | 0.00 Cr | 2.09 Cr | 166.5469 Cr |
| 2023-03-31 | 0.71 Cr | 291.32 Cr | 173.91 Cr | 117.4138 Cr | 37.72 Cr | 37.01 Cr | 65.18 Cr | 13.94 Cr | 5.28 Cr | 0.00 Cr | 1.19 Cr | 168.1349 Cr |
| 2022-03-31 | 0.19 Cr | 245.17 Cr | 131.53 Cr | 113.6373 Cr | 14.16 Cr | 13.97 Cr | 56.12 Cr | 14.47 Cr | 0.89 Cr | 0.00 Cr | 2.80 Cr | 126.7362 Cr |
| 2021-03-31 | 0.64 Cr | 233.04 Cr | 134.18 Cr | 98.8605 Cr | 18.02 Cr | 17.38 Cr | 46.93 Cr | 14.26 Cr | 0.00 Cr | 0.00 Cr | 0.40 Cr | 130.8039 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.8948 Cr | -5.9394 Cr | 4.9237 Cr | -4.3096 Cr | -0.1211 Cr | 1.4733 Cr | -5.2044 Cr | 4.0239 Cr | 3.2337 Cr | 0.0000 Cr | -10.8045 Cr |
| 2024-03-31 | -2.9938 Cr | -1.7023 Cr | 5.5848 Cr | -3.7161 Cr | 0.8886 Cr | 1.5944 Cr | -0.7223 Cr | 4.6837 Cr | -1.1362 Cr | 0.0000 Cr | -5.8566 Cr |
| 2023-03-31 | -1.2811 Cr | 0.4410 Cr | 1.3540 Cr | -2.3251 Cr | 0.5139 Cr | 0.7058 Cr | -1.0440 Cr | 6.0151 Cr | 4.2211 Cr | 0.0000 Cr | -15.1352 Cr |
| 2022-03-31 | -4.4930 Cr | -2.1967 Cr | 2.2534 Cr | -6.6943 Cr | -0.4578 Cr | 0.1919 Cr | -2.2013 Cr | 10.0271 Cr | -3.9786 Cr | 0.0000 Cr | 4.7767 Cr |
| 2021-03-31 | 5.4770 Cr | -2.8793 Cr | -2.4507 Cr | 2.5977 Cr | 0.1470 Cr | 0.6497 Cr | -2.8793 Cr | 8.3014 Cr | -0.0191 Cr | 0.0000 Cr | -1.4646 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 84.16 Cr | 81.36 Cr | 2.80 Cr | 0.0333 | 1.95 Cr | 1.02 Cr | 0.36 | 3.44 Cr | 0.0122 |
| 2025-06-30 | 102.21 Cr | 97.84 Cr | 4.37 Cr | 0.0428 | 1.22 Cr | 1.37 Cr | 0.48 | 3.25 Cr | 0.0134 |
| 2025-03-31 | 108.10 Cr | 108.02 Cr | 0.08 Cr | 0.0007 | -3.43 Cr | 0.47 Cr | 0.17 | 2.69 Cr | 0.0043 |
| 2024-12-31 | 133.79 Cr | 130.39 Cr | 3.40 Cr | 0.0254 | 1.62 Cr | 0.72 Cr | 0.26 | 2.88 Cr | 0.0054 |
| 2024-09-30 | 105.14 Cr | 98.90 Cr | 6.24 Cr | 0.0594 | 3.23 Cr | 1.60 Cr | 0.57 | 3.74 Cr | 0.0152 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 7.19 Cr | 1.00 Cr | 8.19 Cr | 122.34 Cr | 39.12 Cr | 256.36 Cr | 25.09 Cr | 294.00 Cr | 145.15 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 3.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -138.48 Cr |
| 2025-03-31 | 1.47 Cr | 0.00 Cr | 1.47 Cr | 159.55 Cr | 45.48 Cr | 213.28 Cr | 16.22 Cr | 238.27 Cr | 99.79 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -135.59 Cr |
| 2024-09-30 | 1.49 Cr | 0.00 Cr | 1.49 Cr | 23.52 Cr | 29.84 Cr | 251.35 Cr | 12.99 Cr | 274.53 Cr | 138.94 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 1.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,719.50 | ₹4,125,656,480,915.00 | ₹2,507,229.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,427.50 | ₹1,706,299,297,950.00 | ₹252,678.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,816.60 | ₹1,291,710,866,304.00 | ₹38,231.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,269.30 | ₹1,056,708,147,983.00 | ₹594,066.00 |
| Lupin Limited | LUPIN | ₹2,112.40 | ₹964,941,797,794.00 | ₹987,503.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹911.55 | ₹917,232,593,585.00 | ₹304,650.00 |
| Mankind Pharma Limited | MANKIND | ₹2,193.00 | ₹905,281,522,896.00 | ₹254,901.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,206.20 | ₹700,562,917,663.00 | ₹310,348.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,535.00 | ₹661,792,275,000.00 | ₹40,413.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,085.00 | ₹585,744,391,470.00 | ₹940,116.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,010.60 | ₹567,392,946,575.00 | ₹206,565.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,439.80 | ₹365,283,333,076.00 | ₹99,953.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,681.60 | ₹335,027,369,318.00 | ₹50,412.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,818.60 | ₹284,885,428,582.00 | ₹173,611.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,428.00 | ₹270,698,605,800.00 | ₹106,441.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,434.30 | ₹233,062,517,997.00 | ₹695,817.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,879.00 | ₹221,975,000,000.00 | ₹26,353.00 |
| Eris Lifesciences Limited | ERIS | ₹1,525.90 | ₹207,853,353,977.00 | ₹56,044.00 |
| Cohance Lifesciences Limited | COHANCE | ₹537.35 | ₹205,572,452,679.00 | ₹296,235.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹14,978.00 | ₹192,166,077,442.00 | ₹46,872.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,074.60 | ₹170,322,418,251.00 | ₹67,409.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹852.20 | ₹167,511,094,273.00 | ₹17,300.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹908.50 | ₹162,721,316,895.00 | ₹282,805.00 |
| Granules India Limited | GRANULES | ₹617.35 | ₹149,811,531,823.00 | ₹481,472.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,915.80 | ₹145,623,207,197.00 | ₹124,900.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹907.20 | ₹111,296,518,906.00 | ₹24,453.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,644.50 | ₹93,695,211,699.00 | ₹2,919.00 |
| Strides Pharma Science Limited | STAR | ₹911.05 | ₹83,973,951,090.00 | ₹223,908.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.40 | ₹68,344,758,691.00 | ₹115,109.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹742.50 | ₹67,305,615,795.00 | ₹84,177.00 |
| FDC Limited | FDC | ₹407.25 | ₹66,304,406,709.00 | ₹39,532.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹321.25 | ₹62,830,658,390.00 | ₹214,001.00 |
| Sequent Scientific Limited | SEQUENT | ₹213.54 | ₹53,347,378,309.00 | ₹488,886.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹443.30 | ₹48,304,301,975.00 | ₹309,621.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹134.03 | ₹43,495,628,440.00 | ₹500,046.00 |
| Innova Captab Limited | INNOVACAP | ₹709.85 | ₹40,621,115,851.00 | ₹24,458.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,362.60 | ₹39,075,076,839.00 | ₹1,618.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹762.60 | ₹38,678,389,473.00 | ₹47,818.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹417.30 | ₹38,086,971,000.00 | ₹159,073.00 |
| Suven Life Sciences Limited | SUVEN | ₹166.14 | ₹36,618,255,332.00 | ₹114,429.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹333.75 | ₹33,469,286,378.00 | ₹49,801.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹445.30 | ₹31,351,680,475.00 | ₹7,778.00 |
| Hikal Limited | HIKAL | ₹233.98 | ₹28,849,909,485.00 | ₹184,565.00 |
Key Executives
Chief Accountant
A. S. Kathawala
Gender: male
Year Born: 1976
Company Secretary & Compliance Officer
Kailash Chand Jethlia
Gender: male
Year Born:
Chairman & MD
Mihir Rajesh Ghatalia
Gender: male
Year Born: 1983
Executive Director
Nimit Rajesh Ghatalia
Gender: male
Year Born: 1996
Chief Financial Officer
Mira Mihir Ghatalia
Gender: female
Year Born:
FAQs about Aarey Drugs & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mihir Rajesh Ghatalia.
What is the current market price of the stock?
The current price is ₹70.77.
What is the 52-week price range?
The range is ₹32.85-100.
What is the market capitalization of the company?
The market capitalization is ₹200.66 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 56.17.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aarey Drugs & Pharmaceuticals Limited (ISIN: INE198H01019) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹200.66 crores and an average daily volume of 114,207 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.